Here's a development in cancer treatment that's worth understanding, even if you're not an oncologist. On Friday, the U.S. Food and Drug Administration signed off on a new combination therapy for chronic lymphocytic leukemia, a slow-growing blood cancer that's one of the most common forms of leukemia in adults. The approval is for AbbVie Inc. (ABBV)'s Venclexta (venetoclax) plus AstraZeneca Plc. (AZN)'s Calquence (acalabrutinib).
Why does this matter? It's the first all-oral, fixed-duration treatment approved for previously untreated CLL patients. That means no infusions, and a defined treatment period instead of indefinite therapy. For patients, that translates to a targeted option that might actually let them take a break from treatment—a pretty significant upgrade in their quality of life.
Venclexta is jointly developed by AbbVie and Roche Holdings AG (RHHBY). The FDA's decision wasn't just a bureaucratic stamp; it was based on solid data from the AMPLIFY Phase 3 trial. The numbers tell the story: 77% of patients on the Calquence-plus-venetoclax combo were progression-free at three years. The standard-of-care chemotherapy group? That number was 67%.
Digging deeper, the median progression-free survival for the new treatment wasn't even reached in the trial, while it was 47.6 months for chemoimmunotherapy. Overall, the combo reduced the risk of disease progression or death by 35% compared to the old standard. That's not just incremental improvement—that's potentially practice-changing.
What's the Market Saying?
Now, let's talk about what the charts are saying about AbbVie's stock. It's currently trading 0.6% above its 20-day simple moving average but 0.5% below its 100-day SMA. That suggests some short-term strength while facing longer-term resistance. Over the past year, shares are up about 11.68%, sitting closer to their 52-week highs than lows.
The technical indicators paint a mixed picture. The RSI is at 50.09—dead neutral, suggesting the stock isn't overbought or oversold. Meanwhile, the MACD is at 1.4054 with a signal line at 0.5798. Since the MACD is above the signal line, that indicates bullish momentum. So you've got neutral RSI plus bullish MACD equals... well, mixed signals. The stock might be stable now, but there could be room to run.
Key resistance sits at $232.50, with support at $218.00.
Sector Context and Analyst Views
Here's where it gets interesting for investors. Despite this positive FDA news, AbbVie is actually underperforming its sector. The stock was up 0.18% recently, while the healthcare sector was basically flat. The healthcare sector itself is ranked 4th out of 11 sectors—middle of the pack—and has dipped 0.63% over the past month.
The stock lagging behind sector trends suggests broader healthcare dynamics might be weighing on investor sentiment more than this specific approval. Though to be fair, the sector has gained 1.29% over the last 90 days, so there might be recovery potential.
Analysts still like the stock overall, giving it a Buy rating with an average price target of $238.47. But recent moves show they're not all on the same page:
- Piper Sandler: Overweight (Raises Target to $299.00) on Feb. 18
- UBS: Neutral (Lowers Target to $230.00) on Feb. 5
- Evercore ISI Group: Outperform (Lowers Target to $228.00) on Feb. 5
So you've got one firm getting more bullish while two others are getting slightly less optimistic—classic Wall Street disagreement.
